Q1 FY27 results: revenue up 19%, PAT up 27%, INR 5 dividend, 2 acquisitions
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.0 pts more than Nifty Smallcap 250 and 4.8 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Lal PathLabs Q1 FY27 consolidated revenue INR 7,977M (up 19.1% YoY), net profit INR 1,705M (up 27.2% YoY), EPS INR 10.15. Board declared interim dividend of INR 5 per share, record date July 30, 2026. Acquired 100% stake in Shahbazkers Diagnostic for INR 200M. Approved 80% stake buy in Sunshine Healthcare Ghana (up to INR 380M) and 30% stake in Neuome Technologies (up to INR 35M). Also granted 119,300 stock options.
Strong Q1 PAT growth of 27% YoY, interim dividend, plus acquisitions in India and Ghana signal healthy growth momentum.